Results 181 to 190 of about 7,490 (233)

Bruton's tyrosine kinase inhibition for the treatment of allergic disorders. [PDF]

open access: yesAnn Allergy Asthma Immunol
Lin EV, Suresh RV, Dispenza MC.
europepmc   +1 more source

小児科学 [PDF]

open access: yes, 2001
二谷 武   +12 more
core   +1 more source

Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. [PDF]

open access: yesJ Neuroinflammation
Langlois J   +12 more
europepmc   +1 more source

Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling. [PDF]

open access: yesMol Cancer Ther
Li W   +14 more
europepmc   +1 more source

Expanded CD16<sup>+</sup>CD56<sup>+</sup>Granzyme B<sup>+</sup> NK like CD8<sup>+</sup> T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia. [PDF]

open access: yesSci Rep
Hastak P   +16 more
europepmc   +1 more source

Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib. [PDF]

open access: yesInt J Mol Sci
Zhao Y   +9 more
europepmc   +1 more source

Bruton’s Tyrosine Kinase in Ankylosing Spondylitis

Spine, 2023
Study Design. Prospective case-control study. Objective. To explore the role of Bruton’s tyrosine kinase (BTK) in ankylosing spondylitis (AS). Summary of Background Data.
Hsien-Tzung, Liao, Chun-Hsiung, Chen
openaire   +2 more sources

Signalling of Bruton's Tyrosine Kinase, Btk

Scandinavian Journal of Immunology, 1999
Bruton's tyrosine kinase, which is encoded by the BTK gene, is a cytoplasmic protein tyrosine kinase (PTK) crucial for B‐cell development and differentiation. It belongs to the Tec family of PTKs containing several domains that are characteristic of signalling molecules.
A J, Mohamed   +3 more
openaire   +2 more sources

Bruton Tyrosine Kinase Degraders

American Journal of Clinical Oncology
Bruton tyrosine kinase (BTK) is a key enzyme involved in B-cell development and signaling, making it a crucial target in the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and non-Hodgkin lymphoma. While BTK inhibitors (BTKi), such as ibrutinib, have been effective, resistance—both intrinsic and acquired—poses a significant ...
Giorgi, Sabakhtarishvili   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy